Our observations, combined with previous reports indicating that Pam3CSK4 reverses CD8+ T-cell exhaustion and enhances both tumor and pathogen-specific T-cell responses in vivo supports the prioritization of this pathway for further study for CD8+ T-cell based shock and kill eradication strategies [40–42]. This evidence concerns the gene CD8A and neoplasm.